We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$612M
AUM Growth
+$115M
Cap. Flow
+$88.3M
Cap. Flow %
14.44%
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80

Top Buys

Rank Stock Value
1
TEO icon
Telecom Argentina
TEO
+$2.03M
2
MEOH icon
Methanex
MEOH
+$1.43M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.32M
4
CGBD icon
Carlyle Secured Lending
CGBD
+$1.31M
5
GEO icon
The GEO Group
GEO
+$1.3M

Top Sells

Rank Stock Value
1
OXSQ icon
Oxford Square Capital
OXSQ
+$2.73M
2
MPLX icon
MPLX
MPLX
+$1.51M
3
MDCO
Medicines Co
MDCO
+$982K
4
GAIN icon
Gladstone Investment Corp
GAIN
+$857K
5
CELG
Celgene Corp
CELG
+$712K

Sector Composition

Rank Sector Weight
1 Financials 20.46%
2 Real Estate 16.88%
3 Energy 14.34%
4 Healthcare 10.85%
5 Materials 9.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
151
Axsome Therapeutics
AXSM
$12.4B
$910K 0.15%
8,801
-2,275
-21% -$91.9K
TBPH icon
152
Theravance Biopharma
TBPH
$874M
$756K 0.12%
29,216
-14,226
-33% -$276K
MNTA
153
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$753K 0.12%
38,162
-19,687
-34% -$315K
KPTI icon
154
Karyopharm Therapeutics
KPTI
$168M
$730K 0.12%
2,540
-410
-14% -$88.9K
ICPT
155
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$693K 0.11%
5,591
-3,120
-36% -$279K
AIMT
156
DELISTED
Aimmune Therapeutics
AIMT
$682K 0.11%
20,386
+7,752
+61% +$217K
REGN icon
157
Regeneron Pharmaceuticals
REGN
$68.8B
$677K 0.11%
1,803
-468
-21% -$157K
STML
158
DELISTED
Stemline Therapeutics, Inc.
STML
$675K 0.11%
63,484
+14,578
+30% +$145K
BMRN icon
159
BioMarin Pharmaceuticals
BMRN
$11.5B
$673K 0.11%
7,956
-610
-7% -$46.1K
OMER icon
160
Omeros
OMER
$709M
$671K 0.11%
47,622
+4,838
+11% +$70.8K
XLRN
161
DELISTED
Acceleron Pharma
XLRN
$671K 0.11%
12,648
+5,927
+88% +$270K
IRWD icon
162
Ironwood Pharmaceuticals
IRWD
$611M
$664K 0.11%
49,885
-16,931
-25% -$187K
GBT
163
DELISTED
Global Blood Therapeutics, Inc.
GBT
$660K 0.11%
8,303
+3,626
+78% +$215K
ALXN
164
DELISTED
Alexion Pharmaceuticals
ALXN
$660K 0.11%
6,101
+38
+0.6% +$4.06K
BIIB icon
165
Biogen
BIIB
$29.9B
$659K 0.11%
2,222
-948
-30% -$263K
FOLD
166
DELISTED
Amicus Therapeutics
FOLD
$659K 0.11%
67,661
+6,608
+11% +$60.5K
INSM icon
167
Insmed
INSM
$23.2B
$657K 0.11%
27,494
+16,885
+159% +$343K
AGIO icon
168
Agios Pharmaceuticals
AGIO
$2.16B
$652K 0.11%
13,663
-755
-5% -$28.5K
AMGN icon
169
Amgen
AMGN
$203B
$651K 0.11%
2,699
-1,240
-31% -$273K
NKTR icon
170
Nektar Therapeutics
NKTR
$2.39B
$648K 0.11%
2,000
+617
+45% +$179K
SGEN
171
DELISTED
Seagen Inc. Common Stock
SGEN
$640K 0.1%
5,604
-4,516
-45% -$479K
RARE icon
172
Ultragenyx Pharmaceutical
RARE
$2.65B
$638K 0.1%
14,936
+2,818
+23% +$116K
VRTX icon
173
Vertex Pharmaceuticals
VRTX
$121B
$637K 0.1%
2,908
-1,160
-29% -$235K
PTCT icon
174
PTC Therapeutics
PTCT
$6.37B
$635K 0.1%
13,226
+6,918
+110% +$294K
SAGE
175
DELISTED
Sage Therapeutics
SAGE
$632K 0.1%
8,753
+4,769
+120% +$587K
5 6
7
8 9

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2019 Portfolio in Review

As of Q4 2019, Virtus ETF Advisers held 532 positions worth $612M, up 23% from $496M the previous quarter. Its ten largest holdings account for 9% of the portfolio.

Virtus ETF Advisers deployed $88.3M of net new capital in Q4 2019, opening 97 new positions and adding to 238 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 24% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Oxford Square Capital, an estimated $2.73M trimmed.

  • Virtus ETF Advisers's largest Q4 2019 buy was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
  • Virtus ETF Advisers added most to Telecom Argentina in Q4 2019, an estimated $2.03M increase.
  • Virtus ETF Advisers's biggest Q4 2019 reduction was Oxford Square Capital, cutting an estimated $2.73M.
  • Virtus ETF Advisers fully exited Medicines Co in Q4 2019, selling an estimated $982K.
  • Virtus ETF Advisers's ten largest holdings make up 9% of its $612M portfolio in Q4 2019.
  • Virtus ETF Advisers opened 97 new positions and closed 80 in Q4 2019.
  • Virtus ETF Advisers's portfolio value rose 23% quarter-over-quarter to $612M.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.